Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of NNC0480-0389 with Semaglutide
NCT04259801Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Feb 2020
- Primary completion
- Mar 2022
- Modality
- Recombinant Proteins and Enzymes, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of NNC0480-0389 in type 2 diabetes mellitus (T2DM), obesity and Overweight (4 arms), sponsored by Novo Nordisk. Primary endpoint: Number of treatment emergent adverse events. Started Feb 2020; status: completed.
02
Drugs
NNC0480-0389
03
Conditions
type 2 diabetes mellitus (T2DM)obesityOverweight
Beyond the preview
Go deeper on NCT04259801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04259801.